<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interleukin-12 (IL-12) has potent antitumor activities </plain></SENT>
<SENT sid="1" pm="."><plain>We examined whether IL-12 enhanced the cytotoxicity of peripheral blood mononuclear cells (PBMNC) and decreased <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells in 30 patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>): 12 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (five in complete remission (CR) and seven in non-CR); six <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>); and 12 MDS (three <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), eight RA with excess of blasts and one <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>PBMNC from patients and five healthy volunteers were cultured at 5 x 10(5)/ml parallel with or without 100 units/ml of IL-12 for 3 days </plain></SENT>
<SENT sid="3" pm="."><plain>Cytotoxicity of PBMNC against K562 cells was assessed by flow cytometry </plain></SENT>
<SENT sid="4" pm="."><plain>To quantify the amount of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells, WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was measured by competitive reverse transcription polymerase chain reaction (RT-PCR), since WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> is considered as a marker of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) in <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The cytotoxicity of non-IL-12-treated PBMNC of 30 patients was 13.4+/-9.3% at the effector to target (E:T) ratio of 20:1, and significantly lower than that of <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (25.7+/-8.4%) </plain></SENT>
<SENT sid="6" pm="."><plain>The cytotoxicity increased to 30.6+/-17.9% in the IL-12-treated PBMNC </plain></SENT>
<SENT sid="7" pm="."><plain>WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in PBMNC of five healthy volunteers was less than 10(3) copies/microg of total <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Following the 3-day IL-12 treatment, mean WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> of PBMNC was reduced from 10(4.8) to 10(4.2) copies/microg of total <z:chebi fb="40" ids="33697">RNA</z:chebi> in six <z:mp ids='MP_0005481'>CML</z:mp> patients, from 10(5.4) to 10(4.8) copies/microg in 12 MDS patients and from 10(5.0) to 10(4.2) copies/microg in five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients in CR, but not reduced in five of seven <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in non-CR </plain></SENT>
<SENT sid="9" pm="."><plain>These results showed that IL-12 significantly enhanced PBMNC cytotoxicity and decreased the quantity of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells in PBMNC of most patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in CR </plain></SENT>
<SENT sid="10" pm="."><plain>IL-12 might be of considerable benefit in the elimination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>